Your browser version may not work well with NCBI's Web applications. More information here...

Recent Activity

Items 1 - 20 of 1035
of 52Next
1:

Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan.

Almasri NM, Al Hamad M.

Breast Cancer Res. 2005;7(5):R598-604. Epub 2005 May 24.

PMID: 16168103 [PubMed - indexed for MEDLINE]

2:

Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.

Ariga R, Zarif A, Korasick J, Reddy V, Siziopikou K, Gattuso P.

Breast J. 2005 Jul-Aug;11(4):278-80.

PMID: 15982396 [PubMed - indexed for MEDLINE]

3:

Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.

Bartlett JM, Ellis IO, Dowsett M, Mallon EA, Cameron DA, Johnston S, Hall E, A'Hern R, Peckitt C, Bliss JM, Johnson L, Barrett-Lee P, Ellis P.

J Clin Oncol. 2007 Oct 1;25(28):4423-30.

PMID: 17906205 [PubMed - indexed for MEDLINE]

4:

Remarkably high frequency of EGFR expression in breast carcinomas with squamous differentiation.

Bossuyt V, Fadare O, Martel M, Ocal IT, Burtness B, Moinfar F, Leibl S, Tavassoli FA.

Int J Surg Pathol. 2005 Oct;13(4):319-27.

PMID: 16273187 [PubMed - indexed for MEDLINE]

5:

Routine assessment of hormonal receptor and her-2/neu status underscores the need for more therapeutic targets in Kenyan women with breast cancer.

Nyagol J, Nyong'o A, Byakika B, Muchiri L, Cocco M, de Santi MM, Spina D, Bellan C, Lazzi S, Kostopoulos I, Luzi P, Leoncini L.

Anal Quant Cytol Histol. 2006 Apr;28(2):97-103.

PMID: 16637512 [PubMed - indexed for MEDLINE]

6:

Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer.

Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limbergen E, Berteloot P, Amant F, Vergote I, Christiaens MR.

J Clin Pathol. 2005 Jun;58(6):611-6.

PMID: 15917412 [PubMed - indexed for MEDLINE]

7:

Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.

Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM.

J Natl Cancer Inst. 2005 Sep 7;97(17):1254-61.

PMID: 16145046 [PubMed - indexed for MEDLINE]

8:

Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.

Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, Seshadri R, Hepp H, Slamon DJ.

J Natl Cancer Inst. 2003 Jan 15;95(2):142-53.

PMID: 12529347 [PubMed - indexed for MEDLINE]

9:

Prognostic variables in invasive breast cancer: contribution of comedo versus noncomedo in situ component.

Brower ST, Ahmed S, Tartter PI, Bleiweiss I, Amberson JB.

Ann Surg Oncol. 1995 Sep;2(5):440-4.

PMID: 7496840 [PubMed - indexed for MEDLINE]

12:

LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.

Saha B, Zhang N, Naritoku WY, Tsao-Wei DD, Groshen SL, Carlsson G, Larsson L, Gustavsson B, Chaiwun B, Taylor CR, Imam SA.

Anticancer Res. 2004 Jul-Aug;24(4):2391-400.

PMID: 15330189 [PubMed - indexed for MEDLINE]

14:

Do we need HER-2/neu testing for all patients with primary breast carcinoma?

Taucher S, Rudas M, Mader RM, Gnant M, Dubsky P, Bachleitner T, Roka S, Fitzal F, Kandioler D, Sporn E, Friedl J, Mittlböck M, Jakesz R.

Cancer. 2003 Dec 15;98(12):2547-53.

PMID: 14669272 [PubMed - indexed for MEDLINE]

15:

Prognostic implications of HER-2 status in steroid receptor-positive, lymph node-negative breast carcinoma.

Peiró G, Adrover E, Aranda FI, Peiró FM, Niveiro M, Sánchez-Payá J.

Am J Clin Pathol. 2007 May;127(5):780-6.

PMID: 17439837 [PubMed - indexed for MEDLINE]

16:

Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.

Prati R, Apple SK, He J, Gornbein JA, Chang HR.

Breast J. 2005 Nov-Dec;11(6):433-9.

PMID: 16297088 [PubMed - indexed for MEDLINE]

17:

Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.

Hussein MR, Abd-Elwahed SR, Abdulwahed AR.

Cell Biol Int. 2008 Jun;32(6):698-707. Epub 2008 Jan 25.

PMID: 18296077 [PubMed - indexed for MEDLINE]

18:

Correlation of HER-2 over-expression with clinico-pathological parameters in Tunisian breast carcinoma.

Ayadi L, Khabir A, Amouri H, Karray S, Dammak A, Guermazi M, Boudawara T.

World J Surg Oncol. 2008 Oct 22;6:112.

PMID: 18945339 [PubMed - in process]

19:

Primary breast cancer phenotypes associated with propensity for central nervous system metastases.

Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R.

Cancer. 2006 Aug 15;107(4):696-704.

PMID: 16826579 [PubMed - indexed for MEDLINE]

20:

Morphologic spectrum of estrogen receptor-negative breast carcinoma.

Scawn R, Shousha S.

Arch Pathol Lab Med. 2002 Mar;126(3):325-30.

PMID: 11860308 [PubMed - indexed for MEDLINE]

Items 1 - 20 of 1035
of 52Next